Literature DB >> 3142083

Uptake and degradation of tissue plasminogen activator in rat liver.

M Einarsson1, B Smedsrød, H Pertoft.   

Abstract

The mechanism of uptake of tissue plasminogen activator (tPA) in rat liver was studied. Radio-iodinated tPA was removed from the circulation after intravenous administration in a biphasic mode. The initial half life, t1/2(alpha), and the terminal phase, t1/2 (beta), were determined to be 0.5 min and 7.5 min, resp. Separation of the liver cells by collagenase perfusion and density centrifugation, revealed that the uptake per cell was two to three times higher in the non-parenchymal cells than in the parenchymal cells. Endocytosis of fluorescein isothiocyanate-labelled or 125I-labelled tPA was studied in pure cultures of liver cells in vitro. Liver endothelial cells and parenchymal cells took up and degraded tPA. Endocytosis was more efficient in liver endothelial cells than in parenchymal cells, and was almost absent in Kupffer cells. Competitive inhibition experiments showing that excess unlabelled tPA could compete with the uptake and degradation of 125I-tPA, suggested that liver endothelial cells and parenchymal cells interact with the activator in a specific manner. Endocytosis of trace amounts of 125I-tPA in cultures of liver endothelial cells and parenchymal cells was inhibited by 50% in the presence of 19 nM unlabelled tPA. Agents that interfere with one or several steps of the endocytic machinery inhibited uptake and degradation of 125I-tPA in both cell types. These findings suggest that 1) liver endothelial cells and parenchymal cells are responsible for the rapid hepatic clearance of intravenously administered tPA; 2) the activator is taken up in these cells by specific endocytosis, and 3) endocytosed tPA is transported to the lysosomes where it is degraded.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142083

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

1.  Intracellular transport of endocytosed proteins in rat liver endothelial cells.

Authors:  G M Kindberg; E Stang; K J Andersen; N Roos; T Berg
Journal:  Biochem J       Date:  1990-08-15       Impact factor: 3.857

2.  Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography?

Authors:  Hunter B Moore; Ernest E Moore; Michael P Chapman; Kirk C Hansen; Mitchell J Cohen; Frederic M Pieracci; James Chandler; Angela Sauaia
Journal:  J Am Coll Surg       Date:  2019-03-29       Impact factor: 6.113

3.  Different receptors mediate the hepatic catabolism of tissue-type plasminogen activator and urokinase.

Authors:  J Krause; W Seydel; G Heinzel; P Tanswell
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

4.  Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins.

Authors:  J Mordenti; S A Chen; J A Moore; B L Ferraiolo; J D Green
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

5.  Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA.

Authors:  M Otter; J Kuiper; R Bos; D C Rijken; T J van Berkel
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

6.  Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.

Authors:  K Okabe; I Kato; S Sato; T Kashiwabara; S Furuta; H Sato; K Tanikawa; R Kumashiro; M Kanayama
Journal:  Gastroenterol Jpn       Date:  1992-02

7.  Characterization of the binding of plasminogen activators to plasma membranes from human liver.

Authors:  G Nguyen; S J Self; C Camani; E K Kruithof
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

8.  alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells.

Authors:  K A Hajjar; C M Reynolds
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

9.  Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.

Authors:  J Kuiper; A Van't Hof; M Otter; E A Biessen; D C Rijken; T J van Berkel
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

10.  Viral cirrhosis: an overview of haemostatic alterations and clinical consequences.

Authors:  Francesca Romana Ponziani; Valerio De Stefano; Antonio Gasbarrini
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-30       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.